Search Results - "Kris, Mark G"

Evolution of systemic therapy for stages I–III non-metastatic non-small-cell lung cancer by Chaft, Jamie E., Rimner, Andreas, Weder, Walter, Azzoli, Christopher G., Kris, Mark G., Cascone, Tina

“…The treatment goal for patients with early-stage lung cancer is cure. Multidisciplinary discussions of surgical resectability and medical operability determine…”
Get full text

Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment by Basch, Ethan, Deal, Allison M, Dueck, Amylou C, Scher, Howard I, Kris, Mark G, Hudis, Clifford, Schrag, Deborah

“…This study assesses overall survival associated with electronic patient-reported symptom monitoring vs usual care during routine cancer treatment…”
Get full text

Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update by Hesketh, Paul J, Kris, Mark G, Basch, Ethan, Bohlke, Kari, Barbour, Sally Y, Clark-Snow, Rebecca Anne, Danso, Michael A, Dennis, Kristopher, Dupuis, L Lee, Dusetzina, Stacie B, Eng, Cathy, Feyer, Petra C, Jordan, Karin, Noonan, Kimberly, Sparacio, Dee, Somerfield, Mark R, Lyman, Gary H

“…Purpose To update the ASCO guideline for antiemetics in oncology. Methods ASCO convened an Expert Panel and conducted a systematic review of the medical…”
Get full text

Antiemetics: ASCO Guideline Update by Hesketh, Paul J, Kris, Mark G, Basch, Ethan, Bohlke, Kari, Barbour, Sally Y, Clark-Snow, Rebecca Anne, Danso, Michael A, Dennis, Kristopher, Dupuis, L Lee, Dusetzina, Stacie B, Eng, Cathy, Feyer, Petra C, Jordan, Karin, Noonan, Kimberly, Sparacio, Dee, Lyman, Gary H

“…To update the guideline to include new anticancer agents, antiemetics, and antiemetic regimens and to provide recommendations on the use of dexamethasone as a…”
Get full text

Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint by Hellmann, Matthew D, MD, Chaft, Jamie E, MD, William, William N, MD, Rusch, Valerie, Prof, Pisters, Katherine M W, Prof, Kalhor, Neda, MD, Pataer, Apar, MD, Travis, William D, Prof, Swisher, Stephen G, Prof, Kris, Mark G, Dr Prof

“…Summary Improvements in outcomes for patients with resectable lung cancers have plateaued. Clinical trials of resectable non-small-cell lung cancers with…”
Get full text

Serpins Promote Cancer Cell Survival and Vascular Co-Option in Brain Metastasis by Valiente, Manuel, Obenauf, Anna C., Jin, Xin, Chen, Qing, Zhang, Xiang H.-F., Lee, Derek J., Chaft, Jamie E., Kris, Mark G., Huse, Jason T., Brogi, Edi, Massagué, Joan

“…Brain metastasis is an ominous complication of cancer, yet most cancer cells that infiltrate the brain die of unknown causes. Here, we identify plasmin from…”
Get full text

Cabozantinib in patients with advanced RET -rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial by Drilon, Alexander, Dr, Rekhtman, Natasha, PhD, Arcila, Maria, MD, Wang, Lu, PhD, Ni, Andy, PhD, Albano, Melanie, Van Voorthuysen, Martine, Somwar, Romel, PhD, Smith, Roger S, Montecalvo, Joseph, MD, Plodkowski, Andrew, MD, Ginsberg, Michelle S, MD, Riely, Gregory J, PhD, Rudin, Charles M, Prof, Ladanyi, Marc, Prof, Kris, Mark G, Prof

“…Summary Background RET rearrangements are found in 1–2% of non-small-cell lung cancers. Cabozantinib is a multikinase inhibitor with activity against RET that…”
Get full text

Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update by Kris, Mark G, Gaspar, Laurie E, Chaft, Jamie E, Kennedy, Erin B, Azzoli, Christopher G, Ellis, Peter M, Lin, Steven H, Pass, Harvey I, Seth, Rahul, Shepherd, Frances A, Spigel, David R, Strawn, John R, Ung, Yee C, Weyant, Michael

“…Purpose The panel updated the American Society of Clinical Oncology (ASCO) adjuvant therapy guideline for resected non-small-cell lung cancers. Methods ASCO…”
Get full text

Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung Adenocarcinomas by ARCILA, Maria E, CHAFT, Jamie E, NAFA, Khedoudja, ROY-CHOWDHURI, Sinchita, LAU, Christopher, ZAIDINSKI, Michael, PAIK, Paul K, ZAKOWSKI, Maureen F, KRIS, Mark G, LADANYI, Marc

“…Activating mutations in the tyrosine kinase domain of HER2 (ERBB2) have been described in a subset of lung adenocarcinomas (ADCs) and are mutually exclusive…”
Get full text

EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics by Arcila, Maria E, Nafa, Khedoudja, Chaft, Jamie E, Rekhtman, Natasha, Lau, Christopher, Reva, Boris A, Zakowski, Maureen F, Kris, Mark G, Ladanyi, Marc

“…In contrast to other primary epidermal growth factor receptor (EGFR) mutations in lung adenocarcinomas, insertions in exon 20 of EGFR have been generally…”
Get full text

Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring BRAF Mutations by PAIK, Paul K, ARCILA, Maria E, FARA, Michael, SIMA, Camelia S, MILLER, Vincent A, KRIS, Mark G, LADANYI, Marc, RIELY, Gregory J

“…BRAF mutations occur in non-small-cell lung cancer. Therapies targeting BRAF mutant tumors have recently been identified. We undertook this study to determine…”
Get full text

HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium by Pillai, Rathi N., Behera, Madhusmita, Berry, Lynne D., Rossi, Mike R., Kris, Mark G., Johnson, Bruce E., Bunn, Paul A., Ramalingam, Suresh S., Khuri, Fadlo R.

“…BACKGROUND Human epidermal growth factor receptor 2 (HER2) mutations have been reported in lung adenocarcinomas. Herein, the authors describe the prevalence,…”
Get full text

Antiemetics: American Society of Clinical Oncology Focused Guideline Update by Hesketh, Paul J, Bohlke, Kari, Lyman, Gary H, Basch, Ethan, Chesney, Maurice, Clark-Snow, Rebecca Anne, Danso, Michael A, Jordan, Karin, Somerfield, Mark R, Kris, Mark G

“…To update a key recommendation of the American Society of Clinical Oncology antiemetic guideline. This update addresses the use of the oral combination of…”
Get full text

Impact of proposed IASLC ATS ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases by Yoshizawa, Akihiko, Motoi, Noriko, Riely, Gregory J, Sima, Cami S, Gerald, William L, Kris, Mark G, Park, Bernard J, Rusch, Valerie W, Travis, William D

“…A new lung adenocarcinoma classification is being proposed by the International Association for the Study of Lung Cancer, American Thoracic Society and…”
Get full text

HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers by Li, Bob T, Ross, Dara S, Aisner, Dara L, Chaft, Jamie E, Hsu, Meier, Kako, Severine L, Kris, Mark G, Varella-Garcia, Marileila, Arcila, Maria E

“…Human epidermal growth factor receptor 2 gene (HER2 [also known as ERBB2]) alterations have been identified as oncogenic drivers and potential therapeutic…”
Get more information

Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers by DOGAN, Snjezana, RONGLAI SHEN, LADANYI, Marc, ANG, Daphne C, JOHNSON, Melissa L, D'ANGELO, Sandra P, PAIK, Paul K, BRZOSTOWSKI, Edyta B, RIELY, Gregory J, KRIS, Mark G, ZAKOWSKI, Maureen F

“…The molecular epidemiology of most EGFR and KRAS mutations in lung cancer remains unclear. We genotyped 3,026 lung adenocarcinomas for the major EGFR (exon 19…”
Get full text

Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update by BASCH, Ethan, PRESTRUD, Ann Alexis, MORROW, Gary, RAO, Kamakshi V, SCHWARTZ, Rowena N, LYMAN, Gary H, HESKETH, Paul J, KRIS, Mark G, FEYER, Petra C, SOMERFIELD, Mark R, CHESNEY, Maurice, CLARK-SNOW, Rebecca Anne, FLAHERTY, Anne Marie, FREUNDLICH, Barbara

“…To update the American Society of Clinical Oncology (ASCO) guideline for antiemetics in oncology. A systematic review of the medical literature was completed…”
Get full text

Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium by Steuer, Conor E., Behera, Madhusmita, Berry, Lynne, Kim, Sungjin, Rossi, Michael, Sica, Gabriel, Owonikoko, Taofeek K., Johnson, Bruce E., Kris, Mark G., Bunn, Paul A., Khuri, Fadlo R., Garon, Edward B., Ramalingam, Suresh S.

“…BACKGROUND The discovery of oncogenic drivers has ushered in a new era for lung cancer, but the role of these mutations in different racial/ethnic minorities…”
Get full text

Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer by JACKMAN, David, PAO, William, RIELY, Gregory J, ENGELMAN, Jeffrey A, KRIS, Mark G, JÄNNE, Pasi A, LYNCH, Thomas, JOHNSON, Bruce E, MILLER, Vincent A

“…Ten percent of North American patients with non-small-cell lung cancer have tumors with somatic mutations in the gene for the epidermal growth factor receptor…”
Get full text

Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR/KRAS and Presence of PIK3CA/AKT1 Mutations by REKHTMAN, Natasha, PAIK, Paul K, ARCILA, Maria E, TAFE, Laura J, OXNARD, Geoffrey R, MOREIRA, Andre L, TRAVIS, William D, ZAKOWSKI, Maureen F, KRIS, Mark G, LADANYI, Marc

“…There is persistent controversy as to whether EGFR and KRAS mutations occur in pulmonary squamous cell carcinoma (SQCC). We hypothesized that the reported…”
Get full text